Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 208

1.

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane.

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J.

J Clin Oncol. 2015 Jan 20. pii: JCO.2013.52.4892. [Epub ahead of print]

PMID:
25605862
[PubMed - as supplied by publisher]
2.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized controlled trials.

Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ.

Ann Oncol. 2015 Jan 16. pii: mdv003. [Epub ahead of print]

PMID:
25595934
[PubMed - as supplied by publisher]
3.

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A.

Breast Cancer Res Treat. 2015 Jan;149(1):313. doi: 10.1007/s10549-014-3245-7. No abstract available.

PMID:
25573650
[PubMed - in process]
4.

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.

Lancet Oncol. 2014 Dec;15(13):1481-92. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12.

PMID:
25456367
[PubMed - in process]
5.

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A.

Breast Cancer Res Treat. 2014 Dec;148(3):553-61. doi: 10.1007/s10549-014-3144-y. Epub 2014 Nov 8.

PMID:
25381136
[PubMed - in process]
Free PMC Article
6.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju333. doi: 10.1093/jnci/dju333. Print 2014 Dec.

PMID:
25359867
[PubMed - indexed for MEDLINE]
7.

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.

Blagden S, Olmin A, Josephs D, Stavraka C, Zivi A, Pinato DJ, Anthoney A, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves C, Spicer J, Banerji U.

Clin Cancer Res. 2014 Dec 1;20(23):5908-17. doi: 10.1158/1078-0432.CCR-14-1315. Epub 2014 Sep 17.

PMID:
25231405
[PubMed - in process]
8.

Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model.

Shingler SL, Bennett BM, Cramer JA, Towse A, Twelves C, Lloyd AJ.

Curr Med Res Opin. 2014 Nov;30(11):2329-41. doi: 10.1185/03007995.2014.952715. Epub 2014 Aug 29.

PMID:
25105306
[PubMed - in process]
9.

Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.

Valayannopoulos V, Malinova V, Honzík T, Balwani M, Breen C, Deegan PB, Enns GM, Jones SA, Kane JP, Stock EO, Tripuraneni R, Eckert S, Schneider E, Hamilton G, Middleton MS, Sirlin C, Kessler B, Bourdon C, Boyadjiev SA, Sharma R, Twelves C, Whitley CB, Quinn AG.

J Hepatol. 2014 Nov;61(5):1135-42. doi: 10.1016/j.jhep.2014.06.022. Epub 2014 Jun 30.

PMID:
24993530
[PubMed - in process]
Free Article
10.

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C.

Ann Oncol. 2014 Aug;25(8):1536-43. doi: 10.1093/annonc/mdu191. Epub 2014 Jun 9.

PMID:
24915873
[PubMed - in process]
11.

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O'Shaughnessy J.

Oncologist. 2014 Apr;19(4):318-27. doi: 10.1634/theoncologist.2013-0282. Epub 2014 Mar 28.

PMID:
24682463
[PubMed - indexed for MEDLINE]
12.

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.

Calvert H, Twelves C, Ranson M, Plummer R, Fettner S, Pantze M, Ling J, Hamilton M, Lum BL, Rakhit A.

Anticancer Drugs. 2014 Aug;25(7):832-40. doi: 10.1097/CAD.0000000000000099.

PMID:
24637575
[PubMed - in process]
13.

Mathematical and computational models of drug transport in tumours.

Groh CM, Hubbard ME, Jones PF, Loadman PM, Periasamy N, Sleeman BD, Smye SW, Twelves CJ, Phillips RM.

J R Soc Interface. 2014 Mar 12;11(94):20131173. doi: 10.1098/rsif.2013.1173. Print 2014 May 6.

PMID:
24621814
[PubMed - indexed for MEDLINE]
14.

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.

Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S, Schmoll HJ.

Br J Cancer. 2014 Mar 18;110(6):1438-45. doi: 10.1038/bjc.2014.74. Epub 2014 Feb 18.

PMID:
24548866
[PubMed - indexed for MEDLINE]
15.

Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis.

Downing A, Twelves C, Forman D, Lawrence G, Gilthorpe MS.

Breast J. 2014 Jan-Feb;20(1):29-36. doi: 10.1111/tbj.12209. Epub 2013 Nov 13.

PMID:
24438064
[PubMed - indexed for MEDLINE]
16.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.

PMID:
24356624
[PubMed - indexed for MEDLINE]
Free Article
17.

Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.

Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J.

Biochim Biophys Acta. 2013 Dec;1836(2):345-53. doi: 10.1016/j.bbcan.2013.10.005. Epub 2013 Nov 2. Review.

PMID:
24189571
[PubMed - indexed for MEDLINE]
18.

'Being there' for women with metastatic breast cancer: a pan-European patient survey.

Harding V, Afshar M, Krell J, Ramaswami R, Twelves CJ, Stebbing J.

Br J Cancer. 2013 Sep 17;109(6):1543-8. doi: 10.1038/bjc.2013.492. Epub 2013 Sep 3.

PMID:
24002595
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ.

J Clin Oncol. 2013 Oct 10;31(29):3656-63. doi: 10.1200/JCO.2013.49.4344. Epub 2013 Aug 26.

PMID:
23980089
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.

Saito T, Iida S, Abe M, Jones K, Kawanishi T, Twelves C.

J Pharm Pharmacol. 2013 Aug;65(8):1168-78. doi: 10.1111/jphp.12065. Epub 2013 May 23.

PMID:
23837584
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk